Leadership & Pay ·
Moderna, Inc. appointed Michael McDonnell to its Board of Directors as a Class II director, effective July 8, 2026
MRNAModerna, Inc.
Moderna, Inc. appointed Michael McDonnell to its Board of Directors as a Class II director, effective July 8, 2026. Mr. McDonnell, a former CFO of Biogen Inc. and IQVIA Holdings Inc., will also serve on the Audit Committee. Concurrently, David Rubenstein transitioned from the Audit Committee to the Nominating and Corporate Governance Committee. Moderna, Inc. is a biotechnology company that develops mRNA technology for vaccines and therapeutics.